This article is more than 5 years old. Information may no longer be current.
Colchicine decreased in-stent restenosis rate in diabetics after PCI
Click Here to Manage Email Alerts
Patients with diabetes who were assigned colchicine after PCI with a bare-metal stent had less neointimal hyperplasia and a decreased in-stent restenosis rate, according to data published in the Journal of the American College of Cardiology.
The double blind, prospective, placebo-controlled study included 196 patients with diabetes (median age, 63.3 years; 128 men) who underwent PCI with a BMS. Patients were randomly assigned colchicine 0.5 mg twice daily or placebo for 6 months. Patients underwent angiography and IVUS to monitor restenosis and neointima formation 6 months after the initial PCI.
According to study results, the angiographic in-stent restenosis rate was 16% in the colchicines group compared with 33% in the control group (OR=0.38; 95% CI, 0.18-0.79). The number needed to treat with colchicine to avoid one case of angiographic in-stent restenosis was six. Researchers reported similar results for IVUS-defined in-stent restenosis (OR=0.42; 95% CI, 0.22-0.81) and a number needed to treat of five.
During angiographic follow-up, late lumen loss in colchicine-treated patients was 1.6 mm2 (interquartile range, 1.0-2.9) and 2.9 mm2 (interquartile range, 1.4-4.8) in the control group.
The most common adverse events in the colchicine group were gastrointestinal related; 16% of patients reported diarrhea or nausea compared with 7% of the placebo group.
“Colchicine is associated with less neointimal hyperplasia and a reduced in-stent restenosis rate when administered to diabetic patients after bare-metal stent replacement,” researchers wrote. “This observation may prove to be useful in patients undergoing percutaneous coronary intervention in whom implantation of a drug-eluting stent is contraindicated or undesirable.”
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts